Walleye Capital LLC Buys New Holdings in ANI Pharmaceuticals, Inc. $ANIP

Walleye Capital LLC purchased a new position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) during the second quarter, HoldingsChannel reports. The fund purchased 106,112 shares of the specialty pharmaceutical company’s stock, valued at approximately $8,784,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Advisors Asset Management Inc. purchased a new stake in ANI Pharmaceuticals during the 1st quarter valued at approximately $28,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of ANI Pharmaceuticals by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,993 shares of the specialty pharmaceutical company’s stock worth $736,000 after buying an additional 470 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of ANI Pharmaceuticals by 0.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company’s stock worth $3,235,000 after buying an additional 423 shares in the last quarter. Jane Street Group LLC bought a new position in shares of ANI Pharmaceuticals during the first quarter worth $2,706,000. Finally, Norges Bank bought a new position in shares of ANI Pharmaceuticals during the second quarter worth $625,000. 76.05% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms recently weighed in on ANIP. Guggenheim cut their target price on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a research note on Monday. Weiss Ratings cut shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday. Wall Street Zen downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Zacks Research lowered ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Finally, Canaccord Genuity Group reduced their target price on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a report on Monday, August 10th. Four analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $105.83.

Insider Buying and Selling at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, CFO Stephen P. Carey sold 2,850 shares of the stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $81.36, for a total transaction of $231,876.00. Following the completion of the transaction, the chief financial officer owned 174,693 shares in the company, valued at $14,213,022.48. This trade represents a 1.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Ori Gutwerg sold 3,162 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $77.00, for a total transaction of $243,474.00. Following the transaction, the senior vice president owned 75,534 shares of the company’s stock, valued at $5,816,118. This trade represents a 4.02% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 18,987 shares of company stock worth $1,546,405 in the last ninety days. Company insiders own 8.10% of the company’s stock.

ANI Pharmaceuticals Stock Up 2.4%

Shares of ANIP opened at $76.54 on Friday. The stock has a market capitalization of $1.76 billion, a price-to-earnings ratio of 16.50 and a beta of 0.44. ANI Pharmaceuticals, Inc. has a 1 year low of $70.15 and a 1 year high of $99.50. The business’s 50 day simple moving average is $80.82 and its 200-day simple moving average is $79.03. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.91 and a quick ratio of 2.41.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, beating analysts’ consensus estimates of $2.04 by $0.17. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The firm had revenue of $266.04 million during the quarter, compared to the consensus estimate of $260.13 million. During the same period in the prior year, the company earned $1.80 EPS. The company’s quarterly revenue was up 25.8% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, equities analysts expect that ANI Pharmaceuticals, Inc. will post 8.03 earnings per share for the current fiscal year.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.